RSD-1235. Cardiome

Curr Opin Investig Drugs. 2003 Mar;4(3):352-4.

Abstract

RSD-1235 is a novel, mixed ion channel antagonist in development by Cardiome Pharma for the potential treatment of heart arrhythmia. By September 2002, phase II trials had been completed and phase III studies were due to commence in 2003.

Publication types

  • Review

MeSH terms

  • Anti-Arrhythmia Agents* / adverse effects
  • Anti-Arrhythmia Agents* / pharmacology
  • Anti-Arrhythmia Agents* / therapeutic use
  • Atrial Fibrillation / drug therapy
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Potassium Channel Blockers* / adverse effects
  • Potassium Channel Blockers* / pharmacology
  • Potassium Channel Blockers* / therapeutic use
  • Sodium Channel Blockers* / adverse effects
  • Sodium Channel Blockers* / pharmacology
  • Sodium Channel Blockers* / therapeutic use

Substances

  • Anti-Arrhythmia Agents
  • Potassium Channel Blockers
  • Sodium Channel Blockers